An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

NCT06449001 ·Status: RECRUITING ·Phase: PHASE3

A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

NCT04058158 ·Status: COMPLETED ·Phase: PHASE3

Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

NCT03427060 ·Status: COMPLETED ·Phase: PHASE2

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

NCT06818474 ·Status: RECRUITING ·Phase: PHASE4

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT05131204 ·Status: TERMINATED ·Phase: PHASE3

Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT06028594 ·Status: NO_LONGER_AVAILABLE

First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)

NCT07285889 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

NCT03116347 ·Status: COMPLETED ·Phase: PHASE4

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

NCT05870475 ·Status: RECRUITING ·Phase: PHASE2

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

NCT04583007 ·Status: NO_LONGER_AVAILABLE

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

NCT03078582 ·Status: COMPLETED ·Phase: PHASE2

Belimumab for Treatment of cGVHD Following Allo-HCT

NCT05604742 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

NCT01832896 ·Status: WITHDRAWN ·Phase: PHASE2

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

NCT01243944 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

NCT05133531 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy

NCT05039580 ·Status: UNKNOWN ·Phase: PHASE4

A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)

NCT02576145 ·Status: COMPLETED ·Phase: PHASE4

Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy

NCT04641884 ·Status: UNKNOWN

A Study of Belimumab in the Prevention of Kidney Transplant Rejection

NCT01536379 ·Status: COMPLETED ·Phase: PHASE2

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT04901936 ·Status: RECRUITING ·Phase: PHASE2

A Study of TAK-881 in Healthy Adults

NCT05059977 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced ex Vivo With the UNC13D LV Vector Expressing the UNC13D cDNA

NCT06736080 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

NCT02038036 ·Status: COMPLETED ·Phase: PHASE3

Ruxolitinib Combined With Dexamethasone for HLH

NCT03795909 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency

NCT03601286 ·Status: RECRUITING ·Phase: PHASE1